NIFTY – non-invasive prenatal test


NIFTY by GenePlanet is a non-invasive, risk-free prenatal test that has over 99% sensitivity for the three most common trisomy conditions present at birth – Down Syndrome, Edwards Syndrome and Patau Syndrome.

NIPT detects genetic abnormalities caused by additional or missing genetic information in the child’s DNA.

The NIPT test detects a wide range of genetic abnormalities in a fetus.

Most comprehensive non-invasive prenatal test:

  • Down (trisomy 21), Edwards (trisomy 18), and Patau (trisomy 13) syndrome
  • Sex chromosome aneuploidies
  • 60 deletion/duplication syndromes
  • Trisomies 9, 16, 22
  • Gender information


Do I need the test?

Genetic abnormalities can occur in any pregnancy. It can be especially valuable for women:

  • 35 years old or older,
  • with a family history of chromosomal conditions,
  • whose other first-trimester screening tests showed high risk of aneuploidy.


Why is the test highly recommended for women 35 years old or older?

The incidence of fetal trisomies is directly related to maternal age. The risk of having a child with Down syndrome grows in a gradual, linear fashion until about age 30 and increases exponentially thereafter.


How is NIPT by GenePlanet different from other tests?

NIPT by GenePlanet is the most advanced, comprehensive, and accurate first-trimester screening test. It gives you valuable information about your baby.

NIPT by GenePlanet has the highest detection rate for most common trisomies (> 99%).

It reduces the number of unnecessary invasive prenatal testing, such as amniocentesis.

It is the best screening test currently available on the market.

Independent studies, including the most extensive study on the use of NIPT in clinical practice on 147,000 pregnant women, showed that NIPT by GenePlanet detects these deficiencies with a 99% detection rate.
NIFTY by Geneplant requires a 10 ml sample of the maternal blood and can be done from the 10th week of pregnancy. Not sooner as there is not enough cell-free fetal DNA in the bloodstream yet.

Cell-free DNA fragments are short fragments of DNA circulating in the blood. During pregnancy, cell-free DNA fragments originating from both the mother and the fetus circulate in the maternal blood.

However, cell-free fetal DNA represents only a minor part of the total cell-free DNA fragments in maternal blood. This poses a significant technical challenge for some NIPT detection methods.


How does NIFTY by GenePlanet deal with this challenge?

First of all, the test requires at least 3.5% fetal fraction (cell-free fetal DNA). Any less and the analysis can’t be done. That’s why NIPT by Geneplant can be done from 10th week on pregnancy onwards as % of the fetal fraction increases with time.

Then the test sequences and analyses millions of fragments of both fetal and maternal DNA from each sample with the help of cutting edge massively parallel sequencing technology.

NIFTY by GenePlanet analyses data across the entire genome and compares chromosomes in the tested sample to the optimal reference chromosomes to accurately determine the presence of a genetic abnormality. If aneuploidies are present, small excesses or deficits in counts of the affected chromosome are detected.

As opposed to the ‘targeted sequencing’ methods employed by some other NIPT tests, this methodology allows for highly accurate results regardless of the clinical symptoms of the patient and a broader range of testing options including for trisomy, sex chromosome aneuploidies, and deletion and duplication syndromes.
Samples are sent daily to our EU based laboratory.

Ultrasound is a screening test that is highly recommended in combination with NIPT. Ultrasound can also detect morphological abnormalities, which are not necessarily caused by genetic abnormalities.